Safety, tolerability, and pharmacokinetics of fluoropezil (DC20), a novel acetylcholinesterase inhibitor: A phase I study in healthy young and elderly Chinese subjects
Open Access
- 26 February 2023
- journal article
- research article
- Published by Wiley in Clinical and Translational Science
- Vol. 16 (5) , 810-822
Abstract
The present study evaluated the safety, tolerability, and pharmacokinetics of fluoropezil (DC20), a novel acetylcholinesterase inhibitor under development for the treatment of Alzheimer's disease (AD) in otherwise healthy young and elderly Chinese subjects. The study of young subjects included the multiple ascending dose (MAD) arm (2 and 6 mg, N = 24) and the food effect arm (4 mg, N = 12) and was followed by the study of elderly subjects who were given (2 and 4 mg, N = 11). The noncompartmental analysis method was used to determine the pharmacokinetic parameters. The pharmacokinetics of fed versus fasted dose administration in the same subjects was assessed by 90% confidence interval. In the MAD arm, the accumulation ratios of DC20 in vivo were 2.29 and 2.15, respectively. In the food effect arm, compared with fasting administration, an area under the concentration-time curve from zero to t after a standard and high-fat diet orally administered slightly increased by about 19% and 29%, and the time to maximum concentration (T-max) was delayed by around 1 h. For elderly study subjects, T-max was 1.5 and 1.25 h, and terminal half-life (t(1/2)) was 77.1 and 74.2 h, respectively. There were no serious adverse events (AEs), whereas gastrointestinal reactions were the most common AEs associated with the study drug. We predicted the safety risks of DC20 in the clinical treatment of AD, which were well-tolerated by the healthy young and elderly subjects. The elimination of DC20 from the body was slower in elderly subjects than in young subjects. This study was approved by the Center for Drug Evaluation, National Medical Products Administration (CTR20181428, CTR20190664, CTR20191878, and CTR20192724).Keywords
All Related Versions
This publication has 15 references indexed in Scilit:
- Alzheimer's Disease: Critical Notes on the History of a Medical ConceptArchives of Medical Research, 2012
- Current and future treatments for Alzheimer’s diseaseTherapeutic Advances in Neurological Disorders, 2012
- Alois Alzheimer and Alzheimer's disease: a centennial perspectiveJournal of Neurochemistry, 2006
- Tau pathology in Alzheimer disease and other tauopathiesBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2005
- Alzheimer's Disease and the Amyloid β ProteinJournal of Neurochemistry, 1999
- Pharmacokinetic and pharmacodynamic profile of donepezil HCl following evening administrationBritish Journal of Clinical Pharmacology, 1998
- An evaluation of the pharmacokinetics of donepezil HCl in patients with moderately to severely impaired renal functionBritish Journal of Clinical Pharmacology, 1998
- Comparison of the Pharmacokinetics of E2020, A New Compound for Alzheimer's Disease, in Healthy Young and Elderly SubjectsThe Journal of Clinical Pharmacology, 1993
- Amyloid plaque core protein in Alzheimer disease and Down syndrome.Proceedings of the National Academy of Sciences of the United States of America, 1985
- Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid proteinBiochemical and Biophysical Research Communications, 1984